[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Webb IJ, Friedberg nW, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H, Houde H, Monroy R, Schmittling R, Freedman AS: Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2002;8(8):429-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.
  • Contamination of hematopoietic stem cells (HSCs) with tumor cells has been associated with increased incidence of relapse in patients with non-Hodgkin's lymphoma following autologous HSC transplantation.
  • We report a pilot clinical trial in which 10 patients with relapsed B-cell non-Hodgkin's lymphoma received high-dose chemotherapy followed by infusion of autologous HSCs depleted of B-cells by high-density microparticles (HDM) coated with anti-CD19 and anti-CD20 monoclonal antibodies (BCell-HDM).
  • In 6 of the 10 patients, B-cells were detectable by immunocytochemical analysis of the apheresis products prior to treatment.
  • Following treatment with the BCell-HDM, no B-cells were detected in the products from 5 of these patients, a result representing a median depletion of >2.2 logs (range, >0.4 to >5.1 logs).
  • All patients received high-dose cyclophosphamide, BCNU (carmustine), and etoposide prior to reinfusion of their B-cell-depleted autologous HSCs.
  • Engraftment was rapid in all cases, with a median time to achieve an absolute neutrophil count of 0.5 x 10(9)/L of 10 days (range, 8-11 days).
  • The median time to achieve a platelet count of 20 x 10(9)/L unsupported by platelet transfusion was 11.5 days (range, 8-17 days).
  • This nonmagnetic negative-depletion technology is simple, rapid, and effective in depleting target cells to undetectable levels, with excellent recovery of nontarget cells.
  • [MeSH-major] B-Lymphocytes. Cell Separation / methods. Hematopoietic Stem Cell Transplantation / methods. Hematopoietic Stem Cells / cytology. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antigens, Differentiation, B-Lymphocyte / immunology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Graft Survival. Hematopoietic Stem Cell Mobilization. Humans. Microspheres. Middle Aged. Pilot Projects. Secondary Prevention. Transplantation, Autologous / methods. Transplantation, Autologous / standards

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12234168.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 66996
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Differentiation, B-Lymphocyte
  •  go-up   go-down


2. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F: Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol; 2003 Jun;121(6):913-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed-onset neutropenia associated with rituximab therapy.
  • The characteristics of severe neutropenia with a delayed onset following administration of rituximab have been evaluated in 53 consecutively treated patients.
  • All but one patient received rituximab for the treatment of non-Hodgkin's lymphoma.
  • Eight episodes of grade 4 neutropenia were detected between 1 and 5 months after rituximab, when administered alone on five occasions, and on three occasions in combination with chemotherapy, where neutrophil counts had recovered prior to the development of neutropenia.
  • Development of neutropenia did not correlate with either the presence of detectable disease or the administration of further treatment.
  • Neutropenia was associated with selective depletion of neutrophil precursors in all but one episode, where it was associated with generalized bone marrow hypoplasia.
  • All episodes developed after a period of either normal or mildly depressed neutrophil counts following treatment with rituximab, and persisted for between several days and several months, before undergoing spontaneous recovery in four instances, and after administration of filgrastim in the remainder.
  • Episodes of neutropenia were associated with disordered immune status manifested by lymphopenia and hypogammaglobulinaemia, raising the possibility that either disturbance of the balance of lymphocyte subsets or an immune dyscrasia induced by rituximab resulted in the development of this type of neutropenia.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / chemically induced
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Leukocyte Count. Male. Middle Aged. Rituximab. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12786803.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


3. Hull MC, Mendenhall NP, Colgan ME: Subdiaphragmatic Hodgkin's disease: the University of Florida experience. Int J Radiat Oncol Biol Phys; 2002 Jan 1;52(1):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subdiaphragmatic Hodgkin's disease: the University of Florida experience.
  • PURPOSE: To assess the long-term outcomes and late effects of patients with subdiaphragmatic Hodgkin's disease.
  • METHODS AND MATERIALS: Twenty-one patients with Stage I and II subdiaphragmatic Hodgkin's disease were treated with curative intent between February 1966 and February 1998 at the University of Florida.
  • Patient characteristics were as follows: mean age, 38.7 years (range, 3-75 years); 20 males and 1 female; 33% lymphocyte predominant, 43% nodular sclerosing, 14% mixed cellularity, 5% lymphocyte depletion, and 5% unclassified Hodgkin's disease.
  • Treatment included inverted Y irradiation (InY) (8 patients), total nodal irradiation (TNI) (7 patients), and combined modality irradiation and chemotherapy (CMT) (6 patients).
  • There were no deaths from Hodgkin's disease.
  • Treatment failures occurred in 1 of 8 patients after InY, 1 of 7 after TNI, and 1 of 6 after CMT.
  • There were 5 second malignant neoplasms and 3 cardiac events, including 4 second malignant neoplasms and 2 cardiac events in the 9 patients > or =40 years old at diagnosis and 1 second malignant neoplasm and 1 cardiac event in the 12 patients <40 years old.
  • All 3 second solid malignancies in this study occurred 7-14 years after treatment in areas receiving 10-20 Gy.
  • CONCLUSIONS: Subdiaphragmatic Hodgkin's disease is an uncommon manifestation with excellent disease control achieved with InY, TNI, and CMT.
  • This subgroup of patients with Hodgkin's disease is predominantly male and older than subgroups with other presentations, which may predispose the group to a higher risk for serious adverse events after treatment.
  • We recommend InY with spleen for clinical Stages IA and nodular sclerosis or lymphocyte-predominant clinical Stage IIA, InY alone for pathologic Stages IA and IIA, and CMT for all Stage I/II patients with greater than three involved sites, B symptoms, bulky disease (>6 cm), central (para-aortic) presentation, or splenic involvement.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Diaphragm. Disease-Free Survival. Female. Florida. Follow-Up Studies. Humans. Inguinal Canal. Male. Mechlorethamine / administration & dosage. Middle Aged. Myocardial Infarction / etiology. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11777634.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; MOPP protocol
  •  go-up   go-down


Advertisement
4. Smolewski P, Robak T, Krykowski E, Blasiñska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E, Zambrano O: Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res; 2000 Mar;6(3):1150-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
  • On the basis of a retrospective study of 327 patients with Hodgkin's disease (HD), the prognostic significance of several factors, accepted previously and recently proposed, has been analyzed with regard to response to treatment and the survival time.
  • The only independent, pretreatment factors negatively influenced by either time of survival or response to treatment were the following: age at diagnosis of more than 45 years, advanced (IIIB/IV) clinical stage, poor clinical status according to Karnofsky's scale (score less than 70), presence of systemic symptoms, mixed cellularity/lymphocyte depletion histological type, multisite peripheral nodal localization of the disease, abdominal lymphadenopathy, and large primary tumor mass (bulky disease).
  • Short time to achieve complete remission (during the first four courses of chemotherapy) has proven to be significantly positive predictive factor.
  • Cumulative dose of cytostatics lower than programmed was a significantly negative prognostic factor that correlated with a shorter time of survival.
  • High activity of serum lactate dehydrogenase correlated moderately with poor response to the first-line treatment but did not influence the survival time.
  • Other clinical, morphological, and biochemical parameters influenced neither the prognosis nor the response to treatment.
  • High expression of proliferating cell nuclear antigen, p53, and BCL-2 correlated with poor response to the treatment and/or short time of survival.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Retrospective Studies. Survival Analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res 2000 May;6(5):2120
  • (PMID = 10741746.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


5. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • The clinical stage (CS) distribution was CS I in 1 patient (0.6%), CS II in 86 (50.5%), CS III in 77 (45.3%) and CS IV in 6 (3.5%) patients.
  • Histologic subtypes included lymphocyte predominance 7.6%, mixed cellularity 47.1%, nodular sclerosis 42.9% and lymphocyte depletion 0.6%.
  • The overall treatment consisted of both EFRT and CHT.
  • The daily dose was 1.5-2 Gy, the total dose for EFRT was 20-40 Gy.
  • RESULTS: Follow-up extended from a minimum of 0,3 years to maximum 25,7 years, with a median observation time 12 years.The 5-, 10-, 15-, and 25-year overall survival (OS) in the whole group was 93% : 86% : 82% : 82%, respectively.
  • The following factors were analyzed for their prognostic influence: age, gender, stage, histologic subtype at first diagnosis, sites of involvement, number of involved lymph node areas, B symptoms, hepatosplenomegaly, anemia, elevated serum LDH, daily dose, total dose, boost and technique used in EFRT.
  • In univariate analysis, independent risk factors were gender (p < 0.001), stage (IIB: IIIA) (p = 0.03), mediastinal involvement (p = 0.03), daily dose (p = 0.01) and total dose (p = 0.02).
  • In multivariate analysis, independent risk factors age < or = 15 years (p < 0.001), male gender (p = 0.005), daily dose < or = 1.5 Gy (p = 0.009), and total dose 26-30 Gy (p = 0.048) were found to positively affect OS.
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


6. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM: Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant; 2003 Dec;32(12):1159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
  • Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after allogeneic stem cell transplantation (SCT).
  • We treated seven patients with DLI for indolent non-Hodgkin's lymphoma relapsed after SCT.
  • In available blood and bone marrow samples, lymphoma cells were analysed by real-time quantitative polymerase chain reaction of t(14;18)-positive cells in follicular lymphoma, and by immunophenotyping in small lymphocytic lymphoma.
  • Evaluable responses to pre-DLI therapy were stable disease in one and partial remission (PR) in two patients.
  • Six patients responded to DLI (complete remission (CR) in four and PR in two).
  • After DLI, acute graft-versus-host disease (GVHD) occurred in 3/6 patients, classified as grade 2, whereas only limited chronic GVHD was seen (n=5).
  • In the remaining patient, not responding to DLI, progressive disease was seen later on; chemotherapy followed by another DLI resulted in CR.
  • In three cases, clinical responses to DLI could be substantiated by molecular or immunophenotypic analysis of lymphoma cells.
  • We conclude that DLI is effective for treatment of indolent lymphoma relapsing after SCT.
  • [MeSH-major] Graft vs Tumor Effect. Lymphocyte Transfusion. Lymphoma, Non-Hodgkin / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Graft vs Host Disease / etiology. Humans. Immunophenotyping. Lymphocyte Depletion. Male. Mechlorethamine / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Peripheral Blood Stem Cell Transplantation. Polymerase Chain Reaction. Prednisolone / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Radiotherapy, Adjuvant. Recurrence. Remission Induction. Rituximab. Tissue Donors. Transplantation, Homologous / adverse effects. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14647270.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 35S93Y190K / Procarbazine; 4F4X42SYQ6 / Rituximab; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMACE-MOPP protocol; VAP-cyclo protocol
  •  go-up   go-down


7. Dadparvar S, Hussain R, Esteves F, Yu JQ, Grewal RK, Arif S, Cruz R, Barbaria CJ, Woods K, Styler MJ: Thallium-201 imaging in evaluation of Hodgkin's disease. Cancer J; 2002 Nov-Dec;8(6):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thallium-201 imaging in evaluation of Hodgkin's disease.
  • PURPOSE: The role of Ga 67 in the evaluation of Hodgkin's disease has been widely established.
  • This prospective study was performed to evaluate the role of Tl 201 imaging in Hodgkin's disease at the time of initial presentation and in the assessment of response to therapy, relapse, and remission.
  • METHODS: Fifty-one consecutive patients (23 female, 28 male) with known Hodgkin's disease underwent 111 Tl 201 and Ga 67 studies.
  • The histopathologies included nodular sclerosis (in 31 cases), mixed cellularity (in 12), lymphocytic predominant (in five), lymphocytic depletion (in one), and unknown (in two).
  • Comparison with Ga 67 imaging, anatomical imaging (computed tomography and/or magnetic resonance imaging), and clinical correlation were performed.
  • Tl 201 imaging was similar in sensitivity, specificity, and accuracy among the nodular sclerosis and the mixed-cellularity Hodgkin's disease.
  • CONCLUSION: Tl 201 imaging offers more specificity with a higher positive predictive value in the diagnosis of Hodgkin's disease.
  • The Ga 67 study is more sensitive than Tl 201 in the detection of disease.
  • Therefore, we recommend Tl 201 imaging in the initial evaluation and assessment of patients' response to radiation therapy and/or chemotherapy.
  • [MeSH-major] Hodgkin Disease / radionuclide imaging. Thallium Radioisotopes

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500856.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Thallium Radioisotopes
  •  go-up   go-down


8. Prajapati V, Mydlarski PR: Rituximab: a B-cell depletion therapy for dermatologic disease. Skin Therapy Lett; 2007 Jul-Aug;12(6):6-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab: a B-cell depletion therapy for dermatologic disease.
  • Rituximab (Rituxan, Genentech/ Biogen Idec) is a genetically engineered chimeric murine/human monoclonal antibody directed against CD20, a B lymphocyte-specific antigen.
  • Initially approved for the treatment of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL), rituximab has been increasingly used to treat a variety of immune-mediated and autoimmune diseases.
  • While anecdotal case reports recommend its "off-label" use in dermatology, randomized clinical trials are required to firmly establish the safety and efficacy of this emerging biologic therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. B-Lymphocytes / immunology. Immunologic Factors / therapeutic use. Lymphocyte Depletion / methods. Skin Diseases / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Autoimmune Diseases / drug therapy. Humans. Lymphoma, B-Cell / drug therapy. Rituximab. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762903.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 31
  •  go-up   go-down


9. Thorek DL, Tsao PY, Arora V, Zhou L, Eisenberg RA, Tsourkas A: In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. PLoS One; 2010;5(5):e10655
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: B cell depletion immunotherapy has been successfully employed to treat non-Hodgkin's lymphoma.
  • In recent years, increasing attention has been directed towards also using B-cell depletion therapy as a treatment option in autoimmune disorders.
  • However, it appears that the further development of these approaches will depend on a methodology to determine the relation of B-cell depletion to clinical response and how individual patients should be dosed.
  • METHODOLOGY/PRINCIPAL FINDINGS: Cellular imaging of the targeted population in vivo may provide significant insight towards effective therapy and a greater understanding of underlying disease mechanics.
  • Following antibody mediated B cell depletion (anti-CD79), NIR-only labeled cells were expeditiously cleared from the circulation and spleen.
  • Interestingly, B cells labeled with both SPIO and NIR were not depleted in the spleen.
  • CONCLUSIONS/SIGNIFICANCE: Whole body fluorescent tracking of B cells enabled noninvasive, longitudinal imaging of both the distribution and subsequent depletion of B lymphocytes in the spleen.
  • Quantification of depletion revealed a greater than 40% decrease in splenic fluorescent signal-to-background ratio in antibody treated versus control mice.
  • [MeSH-minor] Animals. Cells, Cultured. Fluorescence. Lymphocyte Depletion. Magnetic Resonance Imaging. Mice. Mice, Inbred C57BL. Organ Specificity. Spleen / immunology. Spleen / pathology. Staining and Labeling. Whole Body Imaging

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Nat Biotechnol. 2000 Apr;18(4):410-4 [10748521.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Immunol Methods. 1994 Sep 30;175(1):79-87 [7930641.001]
  • [Cites] Int Immunol. 1997 Nov;9(11):1767-72 [9418137.001]
  • [Cites] Nat Med. 1998 Feb;4(2):245-7 [9461201.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Neurology. 1999 May 12;52(8):1701-4 [10331706.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3410-2; author reply 3412-3 [15525839.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3580-90 [15529346.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):817-26 [15634903.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):4-13 [15616814.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):601-7 [15692974.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1096-102 [15657402.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1103-8 [15657404.001]
  • [Cites] Acad Radiol. 2005 May;12 Suppl 1:S2-6 [16106536.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1407-13 [16258544.001]
  • [Cites] Mol Immunol. 2006 Feb;43(6):613-22 [15899518.001]
  • [Cites] Ann Biomed Eng. 2006 Jan;34(1):23-38 [16496086.001]
  • [Cites] Arthritis Rheum. 2006 May;54(5):1390-400 [16649186.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2793-806 [16947627.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):345-50 [17214580.001]
  • [Cites] Neuroimage. 2007;37 Suppl 1:S47-58 [17611126.001]
  • [Cites] Inflamm Res. 2007 Oct;56(10):391-401 [18026695.001]
  • [Cites] Immunol Invest. 2007;36(5-6):861-85 [18161533.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):676-88 [18272891.001]
  • [Cites] Clin Immunol. 2008 Mar;126(3):282-90 [18226586.001]
  • [Cites] Biomaterials. 2008 Sep;29(26):3583-90 [18533252.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):2961-72 [18713966.001]
  • [Cites] J Immunol. 2008 Oct 1;181(7):4770-9 [18802080.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1724-31 [18250115.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3765-72 [19029438.001]
  • [Cites] Mol Imaging Biol. 2009 May-Jun;11(3):178-87 [19034584.001]
  • [Cites] J Autoimmun. 2009 May-Jun;32(3-4):223-30 [19329279.001]
  • [Cites] AJR Am J Roentgenol. 2009 Aug;193(2):314-25 [19620426.001]
  • [Cites] J Immunol Methods. 2009 Oct 31;350(1-2):194-9 [19647745.001]
  • [Cites] Ann Neurol. 2009 Oct;66(4):460-71 [19847908.001]
  • [Cites] Curr Pharm Biotechnol. 2000 Jul;1(1):1-9 [11467356.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2029-33 [12209504.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2121-31 [12209517.001]
  • [Cites] Ann Rheum Dis. 2002 Oct;61(10):883-8 [12228157.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10):2673-7 [12384926.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9 [12640069.001]
  • [Cites] Muscle Nerve. 2003 May;27(5):611-5 [12707982.001]
  • [Cites] Science. 2003 Oct 24;302(5645):605-8 [14576425.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):971-80 [14999109.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2572-81 [15201414.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2580-9 [15334472.001]
  • [Cites] Immunol Cell Biol. 1999 Dec;77(6):499-508 [10571670.001]
  • [Cites] Cytometry. 1990;11(2):231-8 [1690625.001]
  • (PMID = 20498725.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies
  • [Other-IDs] NLM/ PMC2871797
  •  go-up   go-down


10. Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R: B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica; 2002 Feb;87(2):189-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
  • BACKGROUND AND OBJECTIVES: Rituximab reacts specifically with the CD20 antigen and induces B-cell depletion.
  • DESIGN AND METHODS: Seven patients (one with cold agglutinin disease, two with warm antibody autoimmune hemolytic anemia, four with chronic idiopathic thrombocytopenic purpura) previously refractory to conventional treatments were treated with weekly infusions of rituximab, 375 mg/m2, for 4 weeks.
  • Only treatment with steroids, if strictly necessary, was allowed during the period of rituximab administration, but only patients who reached steroid suspension were considered responders.
  • The pharmacokinetics of rituximab were quantified during therapy and the follow-up period.
  • RESULTS: All patients had marked, even if temporary, B-cell depletion.
  • Three patients, 1 with cold agglutinin disease (CAD) and 2 with chronic idiopathic thrombocytopenic purpura (ITP), had a complete hematologic response.
  • In the patient with cold agglutinin disease a decrease in the agglutinin titer was observed.
  • Treatment tolerance was satisfactory and no infections or other late events were registered.
  • Serum rituximab concentrations appeared to be similar to those calculated in a historical control group of patients with follicular non-Hodgkin's lymphoma who received rituximab as consolidation of response after first-line CHOP chemotherapy.
  • These results, along with data from literature, suggest that this agent may have a therapeutic role in autoimmune diseases.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / therapy. Antibodies, Monoclonal / therapeutic use. Autoimmune Diseases / therapy. B-Lymphocyte Subsets / drug effects. Immunosuppressive Agents / therapeutic use. Immunotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Combined Modality Therapy. Drug Resistance. Female. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Male. Middle Aged. Prednisone / therapeutic use. Purpura, Thrombocytopenic, Idiopathic / drug therapy. Purpura, Thrombocytopenic, Idiopathic / immunology. Purpura, Thrombocytopenic, Idiopathic / therapy. Rituximab. Treatment Outcome


11. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P: Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results. Ann Oncol; 2005 Dec;16(12):1936-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results.
  • BACKGROUND: Hodgkin's disease (HD) accounts for 7.5% of childhood malignancies in Iran.
  • In order to minimize chemotherapy toxicity and avoid eventual hospitalization and psychological and financial burdens we have applied since 1988, for the first time in Iran, a treatment regimen based on subsequently revised DAL-HD 85-90 and later GPOH-HD 95 protocols.
  • PATIENTS AND METHODS: During the period 1988-2004, 40 children with HD received DAL/GPOH-HD-adapted treatment; 25 males (62.5%) and 15 females (37.5%) (male/female ratio 1.7; age 4-14 years, mean 8.8).
  • Clinical evaluation and staging was performed in all patients.
  • Staging was as follows: stage I; seven (17.5%); II, 11 (27.5%); III, 11 (27.5%); and IV, 11 (27.5%).
  • Histopathology: 22 patients had mixed cellularity (MC; 55%), 13 nodular sclerosis (32.5%), four lymphocyte predominance (LP; 10%) and one patient lymphocyte depletion (2.5%).
  • Stage IA and IIA patients (n = 15) received either OPA x2 (vincristine, prednisolone, doxorubicin) or OPPA x2 or OPEA x2 (vincristine, prednisolone, procarbazine and doxorubicin), the latter receiving etoposide instead of procarbazine, and applied to males.
  • Twenty nine patients (72.5%) received radiotherapy (20-25 Gy); four to the involved field (stage I), 25 to the upper mantel (stage II and also III with either residual or mediastinal mass) and three additionally to spleen and para-aortic lymph nodes.
  • Eleven patients received only chemotherapy.
  • Relapse occurred in eight patients (20%); seven stage IV (MC) and one stage IA (LP) with progression to IIIB.
  • Salvage chemotherapy consisted of MOPP/ABVD hybrid; six patients achieved a second sustained remission and three patients died: two due to relapse and progressive disease and the third one in CR, owing to thrombocytopenic hemorrhage and foudroyant pneumonia.
  • Aside from minor acute toxicities, three patients demonstrated azoospermia at the age of 18 years and one of these patients suffered non-Hodgkin lymphoma as a second malignancy.
  • Both received appropriate treatment and are over 10 years in CR.
  • CONCLUSIONS: The DAL/GPOH-HD-based treatment approach proved to achieve long-term sustained cure even in children with advanced HD disease.
  • The essentially outpatient diagnosis and treatment modus did not compromise the disease outcome, and was well tolerated and accepted by the patients and their parents.
  • The employed drugs are easily available and affordable.
  • This treatment approach is suitable for ambulatory use in developing countries.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157620.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Balwierz W, Klekawka T, Moryl-Bujakowska A, Matysiak M, Sopyło B, Wachowiak J, Kaczmarek-Kanold M, Sońta-Jakimczyk D, Janik-Moszant A, Chybicka A, Chaber R, Kowalczyk JR, Mitura-Lesiuk M, Balcerska A, Stachowicz-Stencel T, Wysocki M, Kołtan A, Krawczuk-Rybak M, Muszyńska-Rosłan K, Młynarski W, Stolarska M, Sobol G, Wieczorek M, Karolczyk G, Urbanek-Dadela A: [Can children with Hodgkin's disease be treated with chemotherapy only?]. Przegl Lek; 2010;67(6):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can children with Hodgkin's disease be treated with chemotherapy only?].
  • [Transliterated title] Czy dzieci z choroba Hodgkina moga być leczone wyłacznie chemioterapia?
  • Currently over 90% of children and adolescents with Hodgkin's disease (HD) can be cured thanks to use of multidrug chemotherapy (CT) combined with involved-field radiotherapy (IF-RT).
  • However, the intensive treatment may increase the risk of late complications which may impair the patients' quality of life.
  • In order to decrease the incidence of late complications the protocol with limited use of IF-RT was introduced in centers of Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG).
  • This study presents the treatment results of patients treated with CT only in comparison with the therapy results of children treated with CT and IF-RT.
  • In 45 patients with IA-IIA stages presenting favorable risk factors (small mediastinal tumor, peripheral nodular mass of a maximum diameter < 6 cm, involvement of less than three nodular regions, ESR < 50 mm after 1 h, histologic type other than lymphocyte depletion and very good treatment response assessed after 3 CT cycles) IF-RT was omitted.
  • Our results show that the use of CT only in precisely selected group of patients with HD do not impair the treatment results and may decrease the risk of late life threatening complications.
  • Treatment response assessment with the use of PET may in future increase the number of patients treated without RT and limit the need of the use of invasive diagnostic methods in patients with residual mass.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344765.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


13. Tedder TF, Baras A, Xiu Y: Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol; 2006 Dec;28(4):351-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
  • Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven effective for treating non-Hodgkin's lymphoma and autoimmune disease.
  • CD19 antibody immunotherapy is also effective in mouse models of lymphoma and autoimmunity.
  • In both cases, mouse models have demonstrated that effector cell networks effectively deplete the vast majority of circulating and tissue B lymphocytes through Fcgamma receptor-dependent pathways.
  • In mice, B cell depletion is predominantly, if not exclusively, mediated by monocytes.
  • CD20 mAbs rapidly deplete circulating and tissue B cells in an antibody isotype-restricted manner with a hierarchy of antibody effectiveness: IgG2a/c > IgG1 > IgG2b >> IgG3.
  • Depending on antibody isotype, mouse B cell depletion is regulated by FcgammaRI-, FcgammaRII-, FcgammaRIII-, and FcgammaRIV-dependent pathways.
  • The potency of IgG2a/c mAbs for B cell depletion in vivo results from FcgammaRIV interactions, with likely contributions from high-affinity FcgammaRI.
  • IgG1 mAbs induce B cell depletion through preferential, if not exclusive, interactions with low-affinity FcgammaRIII, while IgG2b mAbs interact preferentially with intermediate-affinity FcgammaRIV.
  • By contrast, inhibitory FcgammaRIIB-deficiency significantly increases CD20 mAb-induced B cell depletion at low mAb doses by enhancing monocyte function.
  • These results provide a molecular basis for earlier observations that human FcgammaRII and FcgammaRIII polymorphisms correlate with the in vivo effectiveness of CD20 antibody therapy.
  • That the innate monocyte network depletes B cells through FcgammaR-dependent pathways during immunotherapy has important clinical implications for CD19, CD20, and other antibody-based therapies for the treatment of diverse B cell malignancies and autoimmune disease.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / immunology. B-Lymphocytes / drug effects. Humans. Immunotherapy. Lymphocyte Depletion. Lymphoma, Non-Hodgkin / drug therapy

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] Blood. 1992 Aug 15;80(4):863-78 [1498329.001]
  • [Cites] Blood. 1993 May 15;81(10):2658-63 [8490175.001]
  • [Cites] Cancer Immunol Immunother. 2000 Mar;48(12):673-83 [10752475.001]
  • [Cites] Immunity. 1996 Aug;5(2):181-8 [8769481.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):1-9 [16385491.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] J Exp Med. 1996 Dec 1;184(6):2385-92 [8976192.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Aug;79(15):4761-5 [6289317.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):3026-32 [9743367.001]
  • [Cites] Science. 2001 Jan 19;291(5503):484-6 [11161202.001]
  • [Cites] Cancer Immunol Immunother. 1995 Jan;40(1):37-47 [7530170.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:221-40 [11722986.001]
  • [Cites] J Immunol Methods. 2001 Feb 1;248(1-2):103-11 [11223072.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3783-8 [2472198.001]
  • [Cites] Blood. 1988 Jan;71(1):13-29 [3257143.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Immunol Methods. 1994 Sep 14;174(1-2):83-93 [8083541.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2738-43 [14551143.001]
  • [Cites] Br J Haematol. 2002 Sep;118(4):959-67 [12199773.001]
  • [Cites] Blood. 1998 Dec 1;92(11):3997-4002 [9834201.001]
  • [Cites] J Immunol. 2005 Apr 1;174(7):4389-99 [15778404.001]
  • [Cites] Rheumatology (Oxford). 2001 Feb;40(2):205-11 [11257159.001]
  • [Cites] Blood. 1984 Jun;63(6):1424-33 [6609729.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6635-43 [11086109.001]
  • [Cites] Immunology. 1979 Dec;38(4):687-95 [521057.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1659-69 [15210744.001]
  • [Cites] Immunity. 1997 Feb;6(2):107-18 [9047233.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10):2673-7 [12384926.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):954-66 [16936269.001]
  • [Cites] Nat Genet. 1998 May;19(1):56-9 [9590289.001]
  • [Cites] Blood. 2002 Jan 1;99(1):67-74 [11756154.001]
  • [Cites] J Exp Med. 2000 Apr 17;191(8):1293-302 [10770797.001]
  • [Cites] Cancer Immunol Immunother. 1995 Jul;41(1):53-60 [7543822.001]
  • [Cites] Immunity. 2002 Mar;16(3):391-402 [11911824.001]
  • [Cites] Autoimmun Rev. 2003 Mar;2(2):101-8 [12848966.001]
  • [Cites] Immunol Res. 2002;26(1-3):177-89 [12403356.001]
  • [Cites] J Virol. 2002 Jan;76(1):432-5 [11739710.001]
  • [Cites] J Cell Biol. 1993 Jun;121(5):1121-32 [7684739.001]
  • [Cites] Infect Immun. 1990 Jun;58(6):1914-8 [2187813.001]
  • [Cites] Leukemia. 2002 Apr;16(4):693-9 [11960351.001]
  • [Cites] Leuk Lymphoma. 1995 Aug;18(5-6):385-97 [8528044.001]
  • [Cites] Biochem Soc Trans. 1997 May;25(2):705-8 [9191187.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2038-40 [15470484.001]
  • [Cites] Trends Immunol. 2001 Sep;22(9):510-6 [11525942.001]
  • [Cites] Immunity. 1995 Jul;3(1):39-50 [7542548.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):30-7 [9933083.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):43-51 [10561017.001]
  • [Cites] J Immunol. 1998 Jan 1;160(1):20-3 [9551950.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):807-11 [11843813.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3884-94 [7515149.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4750-7 [9845541.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):509-15 [9695966.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):1078-87 [15378059.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Cancer Immunol Immunother. 1991;32(6):364-72 [1706642.001]
  • [Cites] Nat Rev Immunol. 2002 Aug;2(8):580-92 [12154377.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1045-52 [12393541.001]
  • [Cites] Am J Hematol. 1992 Aug;40(4):259-63 [1380203.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Immunity. 2003 Apr;18(4):573-81 [12705859.001]
  • [Cites] J Exp Med. 1987 Jan 1;165(1):64-9 [3794607.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):817-26 [15634903.001]
  • [Cites] Adv Immunol. 2005;88:1-50 [16227086.001]
  • [Cites] J Exp Med. 2006 Mar 20;203(3):743-53 [16520392.001]
  • [Cites] Immunol Today. 1990 Nov;11(11):406-10 [2078294.001]
  • [Cites] J Immunol. 1987 Nov 15;139(10):3521-6 [3119711.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1581-7 [12874252.001]
  • [Cites] J Exp Med. 2002 Mar 18;195(6):665-72 [11901193.001]
  • [Cites] Cell. 1994 Feb 11;76(3):519-29 [8313472.001]
  • [Cites] J Immunol. 1985 Sep;135(3):2183-6 [2862210.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15178-83 [16217038.001]
  • [Cites] Drugs. 1999 Jul;58(1):79-88; discussion 89-90 [10439931.001]
  • [Cites] J Immunol. 1997 May 15;158(10):4662-9 [9144478.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2771-7 [11675350.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] J Immunol. 1986 Feb 1;136(3):1123-30 [3484499.001]
  • [Cites] J Immunol. 1998 Oct 15;161(8):3862-9 [9780151.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):364-9 [9708202.001]
  • [Cites] J Immunol. 1989 Jul 15;143(2):712-7 [2472450.001]
  • [Cites] Immunol Rev. 2002 Dec;190:123-36 [12493010.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7170-6 [11156427.001]
  • [Cites] Genomics. 2001 Mar 1;72(2):119-27 [11401424.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1352-7 [11520782.001]
  • [Cites] J Immunol. 1992 May 15;148(10):3062-71 [1578132.001]
  • [Cites] Development. 1994 Jun;120(6):1357-72 [8050349.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2392-8 [10499609.001]
  • [Cites] Int Immunol. 2004 Jan;16(1):119-29 [14688067.001]
  • [Cites] J Immunol. 1996 Nov 15;157(10):4371-8 [8906812.001]
  • [Cites] Immunol Today. 1994 Sep;15(9):450-4 [7524522.001]
  • [Cites] J Immunol Methods. 1998 Mar 15;212(2):187-92 [9672206.001]
  • [Cites] J Immunother. 2001 May-Jun;24(3):263-71 [11394505.001]
  • [Cites] Eur J Immunol. 1988 Feb;18(2):313-6 [3350037.001]
  • [Cites] Immunity. 2006 Jan;24(1):19-28 [16413920.001]
  • [Cites] Arthritis Rheum. 2003 Jun;48(6):1484-92 [12794814.001]
  • [Cites] Lancet. 1984 Aug 25;2(8400):427-31 [6147502.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3621-30 [12646626.001]
  • [Cites] Immunogenetics. 2001 Jul;53(5):357-68 [11486273.001]
  • [Cites] Arthritis Rheum. 2003 Feb;48(2):455-9 [12571855.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1739-47 [2224123.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11490-4 [8524789.001]
  • [Cites] Eur J Immunol. 1981 Dec;11(12):1012-6 [7327198.001]
  • [Cites] Immunity. 2004 May;20(5):517-27 [15142521.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3063-73 [16920943.001]
  • [Cites] J Virol. 1992 Jul;66(7):4252-7 [1376367.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1071-9 [12393727.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1925-33 [10657642.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1644-52 [9473230.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5767-72 [1697500.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1329-36 [7509655.001]
  • [Cites] N Engl J Med. 1993 Aug 12;329(7):459-65 [7687326.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] Immunity. 2005 Jul;23(1):41-51 [16039578.001]
  • [Cites] Immunogenetics. 2002 Oct;54(7):463-8 [12389094.001]
  • [Cites] Blood. 1996 May 1;87(9):3803-12 [8611706.001]
  • [Cites] Oncology (Williston Park). 1998 Dec;12(12):1763-9; discussion 1769-70, 1775-7, [9874849.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1689-96 [10587359.001]
  • (PMID = 17091246.001).
  • [ISSN] 0344-4325
  • [Journal-full-title] Springer seminars in immunopathology
  • [ISO-abbreviation] Springer Semin. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20
  •  go-up   go-down


14. Büyükpamukçu M, Varan A, Akyüz C, Atahan L, Ozyar E, Kale G, Köksal Y, Kutluk T: The treatment of childhood Hodgkin lymphoma: improved survival in a developing country. Acta Oncol; 2009;48(1):44-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of childhood Hodgkin lymphoma: improved survival in a developing country.
  • BACKGROUND: To evaluate the clinical characteristics, treatment regimens, and outcome of children with Hodgkin lymphoma in a developing country over a period of 34 years.
  • METHODS: This paper retrospectively evaluates the treatment and prognosis of 614 children with Hodgkin lymphoma disease between 1971 and 2005.
  • All patients were treated with chemotherapy, and also received radiotherapy.
  • RESULTS: There were 452 males and 162 females with a median age of 8 years (2 to 21); 183 patients had B symptoms.
  • There were 165, 185, 145, and 119 patients in stage I, II, III, and IV, respectively.
  • Histopathologic subtypes were mixed cellularity (344 patients), nodular sclerosis (90), lymphocytic predominance (62), lymphocytic depletion (46), unclassified types (69), and nodular lymphocyte predominant Hodgkin lymphoma (3).
  • Overall (OS) and event-free survival (EFS) rates were 83 and 60%, though OS rates varied according to chemotherapy protocol; age; presence of B symptoms, leukocytosis, anemia, and extranodal involvement; and stage at diagnosis.
  • Over the years, the median age of patients increased, as did the frequency of the nodular sclerosing type of disease.
  • The increase in the median age and in the frequency of the nodular-sclerosing type are thought to be related to the development status of Turkey.
  • The ABVD protocol yielded the best survival rates and should be used for treatment of patients with Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Male. Multivariate Analysis. Neoplasm Staging. Survival Rate. Treatment Outcome. Turkey / epidemiology. Young Adult


15. Coşkun HŞ, Eser B, Çetin M, Er Ö, Ünal A, Altınbaş M, Karahacıoğlu E, Kaplan B: Hodgkin's Disease: Results of a Single Center in Central Anatolia. Turk J Haematol; 2001 Jun 5;18(2):117-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's Disease: Results of a Single Center in Central Anatolia.
  • Hodgkin's Disease (HD) accounts for about 1% of newly diagnosed malignant diseases.
  • The patients' age ranged from 15 to 72 years with a median of 41.5 years.
  • Of the patients 10.1% was stage I, 29.4% stage II, 39.5% stage III, and 21.0% stage IV.
  • According to Rye classification frequency of histologic subtypes was as follows; 21.0% lymphocyte predominant, 25.2% nodular sclerosis, 43.7% mixed cellularity, and 10.1% lymphocyte depletion.
  • Combination chemotherapy consisting cyclophosphamide, vincristine, procarbazine and prednisolone (COPP) was used as first line treatment in 59.7% of patients.
  • Disease progression or recurrence was observed in 30.2% of patients.
  • Five year survival rate was found as 70.8% of all patients, 90.1% for stage I-II, 55.3% for stage III-IV patients (p= 0.03).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264066.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


16. Martinelli G, Laszlo D, Bertolini F, Pastano R, Mancuso P, Calleri A, Vanazzi A, Santoro P, Cavalli F, Zucca E: Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol; 2003 Oct;123(2):271-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma.
  • We investigated the toxicity and efficacy of the chimaeric anti-CD20 antibody rituximab in combination with standard-dose chlorambucil in newly diagnosed and relapsed/refractory indolent B-cell lymphoma patients.
  • A total of 29 patients (15 newly diagnosed and 14 relapsed/refractory) with low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) were included in this phase II study.
  • Therapy consisted of chlorambucil 6 mg/m2/d for 6 consecutive weeks in combination with a standard 4-weekly rituximab administration schedule in the induction phase.
  • Patients responding to the induction therapy received four additional cycles with chlorambucil (6 mg/m2/d for 2 weeks/month) plus rituximab (once a month).
  • Twenty-six patients (89%) completed the treatment; only one patient discontinued treatment because of haematological toxicity.
  • At the end of the study, the dose of chlorambucil had to be reduced in seven patients (27%) and six patients (23%) required a delay in further treatment, as a result of toxicity during consolidation therapy.
  • Only one patient was withdrawn from the study because of progressive disease; the 27 patients evaluable for response at the end of consolidation achieved a clinical response (63% complete response and 26% partial response).
  • A significant CD4+ and CD56+ depletion was observed after induction and during consolidation therapy; two herpes zoster virus infections and one perianal abscess represented major infectious morbidities registered during the study.
  • Its definitive role in the treatment of low-grade NHL should be further evaluated in randomized trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / drug effects. Chlorambucil / administration & dosage. Chlorambucil / adverse effects. Drug Administration Schedule. Female. Hematologic Diseases / chemically induced. Humans. Lymphocyte Count. Male. Middle Aged. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14531908.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 18D0SL7309 / Chlorambucil; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


17. Thompson LD, Fisher SI, Chu WS, Nelson A, Abbondanzo SL: HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol; 2004 May;121(5):727-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases.
  • We retrospectively analyzed 45 cases of HIV-associated Hodgkin lymphoma (HIV-HL).
  • HIV-HL generally is a disease of young white men (mean age, 40.1 years) who acquired HIV infection by homosexual or bisexual behavior (68%), intravenous drug use (24%), and/or blood transfusion (8%).
  • The mean interval between the diagnosis of HIV and HIV-HL was 5.2 years.
  • Morphologic classification of nodal biopsy specimens (2001 World Health Organization criteria) included 15 mixed cellularity Hodgkin lymphomas (MCHLs), 14 nodular sclerosis Hodgkin lymphomas (NSHLs), 9 lymphocyte depleted Hodgkin lymphomas (LDHLs), and 7 classic Hodgkin lymphomas, type not further categorized.
  • The Hodgkin-Reed-Sternberg (HRS) cells expressed positive immunoreactivity with fascin (30/30 [100%]), CD30 (35/37 [95%]), CD15 (32/36 [89%]), bcl-X(L) (25/31 [81%]), bcl-2 (15/29 [52%]), CD20 (4/34 [12%]), bcl-6 (3/28 [11%]), and Epstein-Barr virus latent membrane protein-1 (32/33 [97%]) and were nonreactive for CD138/syndecan-1.
  • At diagnosis, most patients (n = 27) had high-stage disease (IV(E)) associated with an aggressive course (16% 5-year survival).
  • LDHL behaved more aggressively than MCHL and NSHL (15% vs 40%, 5-year survival, respectively), as did disease with a sarcomatoid pattern (11% 5-year survival).
  • Chemotherapy and radiotherapy proved efficacious in a minority of these patients.
  • [MeSH-major] HIV Infections / pathology. Hodgkin Disease / pathology. Lymphoma, AIDS-Related / pathology


18. Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP: Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol; 2001;18(2):99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
  • Campath-1H has been used in B-chronic lymphocytic leukemia (B-CLL), T-prolymphocytic leukemia (T-PLL), and low-grade non-Hodgkin's lymphoma (LGNHL).
  • The responses (complete [CR] and partial [PR]) obtained in untreated B-CLL patients are of the order of 90%.
  • Because of the antibody's higher activity on circulating lymphocytes, it has been used for in vivo purging of residual disease in B-CLL, followed by autologous stem-cell transplantation.
  • In heavily pretreated advanced stage LGNHL, response is achieved only in 14% of cases with B-phenotype; a 50% response rate is noted in mycosis fungoides.
  • The main complications of Campath-1H treatment are caused by tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 release, usually during the first intravenous infusion, and include fever, rigor, nausea, vomiting, and hypotension responsive to steroids.
  • Immunosupression resulting from normal B- and T-lymphocyte depletion is frequent, resulting in an increased risk for opportunistic infections.
  • More clinical trials in a larger number of patients are necessary to determine the exact role and indications of Campath-1H in lymphoproliferative disorders.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, B-Cell / drug therapy. Leukemia, Prolymphocytic / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Dose-Response Relationship, Drug. Humans. Immunosuppression. Infection. Infusions, Intravenous. Interleukin-6 / adverse effects. Interleukin-6 / secretion. Phenotype. Risk Factors. Treatment Outcome. Tumor Necrosis Factor-alpha / adverse effects. Tumor Necrosis Factor-alpha / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1996 Dec 15;98(12):2819-26 [8981930.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):669-72 [9207420.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):151-3 [8611450.001]
  • [Cites] Med Oncol. 2000 Feb;17(1):70-3 [10713664.001]
  • [Cites] Tissue Antigens. 1990 Mar;35(3):118-27 [2165283.001]
  • [Cites] Leuk Lymphoma. 1996 Dec;24(1-2):93-101 [9049965.001]
  • [Cites] Lancet. 1992 Sep 26;340(8822):748-52 [1356177.001]
  • [Cites] Transplantation. 1988 Apr;45(4):753-9 [3282358.001]
  • [Cites] Biotechnology (N Y). 1991 Jan;9(1):64-8 [1367214.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):65-74 [9482528.001]
  • [Cites] Bone Marrow Transplant. 1996 May;17(5):819-24 [8733704.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:113-7 [27463491.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4581-90 [9845524.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 5):12-7 [10528911.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):754-60 [10792280.001]
  • [Cites] J Clin Pathol. 1994 Apr;47(4):313-7 [8027367.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):219-35 [7612488.001]
  • [Cites] Blood. 1983 Oct;62(4):873-82 [6349718.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):506-15 [7734348.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):52-7 [10561018.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):198-208 [10319388.001]
  • [Cites] Blood. 1989 May 1;73(6):1431-9 [2713487.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):305-8 [8704678.001]
  • [Cites] Blood. 1984 Nov;64(5):1085-93 [6333257.001]
  • [Cites] Lancet. 1988 Dec 17;2(8625):1394-9 [2904526.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):61-4 [7858503.001]
  • [Cites] J Rheumatol. 1996 Jun;23(6):1103-6 [8782148.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3257-63 [9779699.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] Eur J Immunol. 1991 Jul;21(7):1677-84 [1711975.001]
  • [Cites] Br J Haematol. 1993 Jul;84(3):542-4 [8217808.001]
  • [Cites] Lancet. 1993 Apr 17;341(8851):1037 [8096935.001]
  • [Cites] Mol Biol Med. 1983 Oct;1(3):305-19 [6390085.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):104-14 [10319379.001]
  • [Cites] Leuk Lymphoma. 1997 May;25(5-6):479-86 [9250818.001]
  • [Cites] Exp Hematol. 1999 Jul;27(7):1210-8 [10390197.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] Eur J Immunol. 1988 Oct;18(10):1507-14 [2973413.001]
  • [Cites] Curr Opin Oncol. 1996 Sep;8(5):353-9 [8914801.001]
  • [Cites] Transplantation. 1999 Feb 27;67(4):620-6 [10071037.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):5-13 [9020367.001]
  • [Cites] N Engl J Med. 1990 Jul 26;323(4):250-4 [2366834.001]
  • [Cites] Leuk Lymphoma. 1990;2(3-4):179-93 [27456733.001]
  • [Cites] Curr Opin Hematol. 1998 Jul;5(4):237-43 [9747629.001]
  • [Cites] Nature. 1988 Mar 24;332(6162):323-7 [3127726.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):209-16 [10319389.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1165-71 [9694704.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • (PMID = 11778765.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 3A189DH42V / alemtuzumab
  • [Number-of-references] 60
  •  go-up   go-down


19. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H, GESIDA Group, GELCAB Group: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica; 2007 Feb;92(2):191-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for Hodgkin's lymphoma (HL), information on the results of this therapy in human immunodeficiency (HIV)-related HL is scarce.
  • We analyzed the results of the ABVD regimen and highly active antiretroviral therapy (HAART) in patients with advanced stage, HIV-related HL.
  • Response to chemotherapy, overall survival (OS) and event-free survival (EFS) were recorded.
  • RESULTS: The median age of the patients was 37 years (range, 24-61) and 29 (47%) had a previously known diagnosis of acquired immunodeficiency syndrome.
  • The median CD4 lymphocyte count at diagnosis was 129/muL (range 5-1,209).
  • The histologic subtype of HL was nodular sclerosis in 17 patients (27%), mixed cellularity in 25 (41%), lymphocyte depletion in 10 (16%) and non-specified in the remaining 10 (16%).
  • Twenty-one (34%) patients were in stage III and 41 (66%) in stage IV.
  • INTERPRETATION AND CONCLUSIONS: In patients with advanced stage, HIV-related HL, treatment with ABVD together with HAART is feasible and effective.
  • This supports the concept that patients with HIV-related HL should be treated in the same way as immunocompetent patients if HAART, adequate supportive therapy and anti-infectious prophylaxis are given concomitantly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Hodgkin Disease / virology. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. CD4-Positive T-Lymphocytes / metabolism. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296568.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


20. Ali A, Sayed H, Farrag A, El-Sayed M: Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study. Leuk Res; 2010 Nov;34(11):1447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study.
  • We conducted a retrospective analysis to investigate the clinical outcome of combined-modality therapy using multiagent chemotherapy and involved-field radiotherapy in treatment of children with Hodgkin's lymphoma.
  • Fifty eight cases with newly diagnosed Hodgkin's lymphoma were analyzed.
  • High-risk disease (stage IIIB and IV), presence of B symptoms, lymphocyte depletion subtype, bulky disease and late response to chemotherapy were poor prognostic factors.
  • Stage-adapted combined-modality therapy resulted in satisfactory outcome in treatment of pediatric Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Prognosis. Radiotherapy. Retrospective Studies. Risk Assessment

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20599270.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Hamaguchi Y: [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy]. Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb;32(1):29-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].
  • Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and autoimmune disease.
  • However, the cellular and molecular pathways for B cell depletion remain undefined and the in vivo effect of immunotherapy on tissue B cells and their subsets is generally unknown.
  • To identify the mechanisms for B cell depletion in vivo, a new mouse model for anti-CD20 immunotherapy was developed using a panel of twelve mouse anti-mouse CD20 monoclonal antibodies.
  • Anti-CD20 antibodies rapidly depleted the vast majority of circulating and tissue B cells in an isotype-restricted manner that was completely dependent on effector cell Fc receptor expression.
  • B cell depletion utilized FcgammaRI-, FcgammaRIII- and FcgammaRIV-dependent pathways, while B cells were not eliminated in FcR common gamma chain-deficient mice.
  • Monocytes were the dominant effector cells for B cell depletion, with no demonstrable role for T or NK cells.
  • Although most anti-CD20 antibodies activated complement in vitro, B cell depletion was completely effective in mice with genetic deficiencies in C3 complement components.
  • The considerable factors that determine the effectiveness of anti-CD20 immunotherapy are following: the expression level of CD20 on B cell surface; the dosage of anti-CD20 mAb; the association of Fcgamma receptor with the isotype of the antibies; B cell subpopulations within different tissues.
  • These findings have important clinical implications for anti-CD20 and other antibody-based therapies.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. B-Lymphocytes / immunology. Lymphocyte Depletion
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Antibody-Dependent Cell Cytotoxicity / immunology. Autoimmune Diseases / drug therapy. Immunotherapy. Lymphoma, Non-Hodgkin / drug therapy. Mice. Receptors, IgG / immunology. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252375.001).
  • [ISSN] 1349-7413
  • [Journal-full-title] Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology
  • [ISO-abbreviation] Nihon Rinsho Meneki Gakkai Kaishi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 14
  •  go-up   go-down


22. Petera J, Macharová H, Pohanková R, Malír A, Coupek P, Konecný M, Patera J, Pecina J, Drbal J, Koukalová H, Vásová I: Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute. Neoplasma; 2000;47(2):129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
  • Radiotherapy and chemotherapy, alone or in combination, are curative treatment methods in early stages of Hodgkin's disease (HD).
  • The choice of treatment depends on the stage of the disease, histological type and localization of the tumor, as well as on other prognostic factors.
  • A retrospective study was conducted including 145 patients with clinical Stages I and II of HD according to Ann Arbor classification, all treated in the Masaryk Memorial Cancer Institute in Brno during the years 1985 through 1994.
  • 41 patients were diagnosed with Stage IA tumor, 1 patient with Stage IB, 75 patients with Stage IIA and 28 with Stage IIB disease.
  • The histological types of the disease were lymphocyte predominant in 23 patients, nodular sclerosis in 49 patients, mixed cellularity in 65 cases and lymphocyte depletion in 8 cases.
  • 39 patients were treated with combination of radiotherapy and chemotherapy.
  • 15 patients were given chemotherapy alone, 7 patients from this group experienced a relapse.
  • The five-year survival was 81% in patients with Stages IA and IIA disease, 65% in Stages IB and IIB disease.
  • Radiotherapy remains the curative method of choice in highly selected group of patients with early stages of Hodgkin's disease.
  • The results of radiotherapy alone are unsatisfactory in unselected clinical Stage I--II patients because of the presence of patients with adverse prognostic factors, particularly B symptomatology, mixed cellularity/lymphocyte depletion histology, higher age.
  • These patients are candidates for combined treatment.
  • Modern equipment and meticulous treatment are conditions crucial for the outcome of curative radiotherapy in patients with Hodgkin's disease.
  • Combination chemotherapy is very effective in the treatment of relapse following the primary radiotherapy.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985481.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SLOVAKIA
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol; MOPP protocol; VBA protocol
  •  go-up   go-down






Advertisement